Sibutramine weight reduction
Quantity: 20mg/100 pills
Active substance: Sibutramine Hydrochloride Monohydrate
What is Sibutramine? For what reason is sibutramine used?
Owing to the possibility of severe cardiovascular complications in some individuals who take it, Sibutramine is no longer available in the U.S.
Sibutramine is recommended for obesity treatment, including weight loss and weight loss maintenance, and should be used in combination with a decreased calorie diet. In obese patients with an initial body mass index of 30 kg/m2, or 27 kg/m2, sibutramine is recommended in the presence of other risk factors (e.g., diabetes, dyslipidemia, controlled hypertension).
By manipulating neurotransmitters within the brain, sibutramine assists in weight loss. In order to interact with other nerves, neurotransmitters are chemicals that are formed and released by nerves. Released neurotransmitters can bind to other nerves or the nerves that release them may pick them up again a process called reuptake. Sibutramine inhibits the reuptake of dopamine, norepinephrine, and serotonin neurotransmitters. The blocking of neurotransmitter reuptake changes the balance of neurotransmitters within the nerve cells and thus affects the function and interaction of the nerves.
Patients taking sibutramine can achieve a reduction in their baseline weight of 10 percent. In addition, sibutramine-assisted weight loss has been followed by blood lipid change (e.g, cholesterol). Sibutramine was approved in 1997 by the FDA.
What side effects does sibutramine have?
In certain patients, Sibutramine significantly raises blood pressure and/or heart rate. Regular blood pressure and pulse rate monitoring is needed when sibutramine is administered.
In placebo-controlled studies of obesity, sibutramine 5 to 20 mg once daily was associated with mean systolic and diastolic blood pressure increases of approximately 1 to 3 mm Hg relative to placebo and mean pulse rate increases of approximately 4 to 5 beats per minute relative to placebo. In some patients, larger increases were observed, especially when sibutramine therapy was initiated at higher doses.
Blood pressure and pulse should be assessed before beginning sibutramine therapy and should be checked regularly afterwards. Either dose reduction or discontinuation should be considered for patients who report a prolonged rise in blood pressure or pulse rate when receiving sibutramine. MERIDIA should be prescribed with caution to patients with a history of high blood pressure and should not be administered to patients with uncontrolled or improperly managed high blood pressure.
Sibutramine is administered once a day, usually in the morning. Therapy typically starts with one tablet of 10 mg a day. After several weeks, the dosage can be raised by the doctor to 15mg to achieve the desired effect. Up to 60mg doses have been studied. It is possible to take sibutramine with or without food.